Protagenic Therapeutics, Inc. has made progress in its clinical trial for a new brain peptide compound called PT00114.

The Phase 1b/2a AMARONE clinical trial's 12-week results indicate that Restoret, developed by Eyebiotech Limited, is well-tolerated in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Medicenna Therapeutics has initiated a Phase 1/2 clinical trial, known as the ABILITY-1 study, to assess the safety and efficacy of MDNA11, a modified version of interleukin-2 (IL-2).

A recent clinical study by Kiromic BioPharma, Inc. has shown positive results in the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) with their drug candidate, Deltacel™.

Carrick Therapeutics has initiated a Phase 1b/2 clinical trial to test the efficacy and safety of a combined treatment of samuraciclib (CT7001) and vepdegestrant (ARV-471) in patients.

AIM ImmunoTech Inc. has initiated a Phase 1b/2 clinical trial at Erasmus Medical Center for patients with advanced pancreatic cancer.

Replicate Bioscience has reported promising initial clinical outcomes for its self-replicating RNA (srRNA) vaccine, RBI-4000, which is designed to combat rabies.

The trial, which is evaluating a continuous subcutaneous delivery of low-dose lenalidomide combined with dexamethasone and bortezomib, is progressing faster than expected.

Biotechnology firm ProJenX has obtained approval from the European Union to conduct a Phase 1 clinical trial, known as PRO-101, for prosetin, a groundbreaking MAP4K inhibitor.

Roivant Sciences has halted the development of its experimental drug RVT-2001 after an interim review of a Phase I/II clinical trial for myelodysplastic syndromes (MDS) revealed insufficient data to continue.

NervGen Pharma Corp. is nearing the completion of participant recruitment for its Phase 1b/2a clinical trial of NVG-291, a potential spinal cord injury treatment.

Osivax, a biopharmaceutical firm, has initiated a Phase 1 clinical trial for its sarbecovirus vaccine candidate, OVX033, in France.